Search Results - "AXELROD, Douglas W"

Optimized clinical performance of growth hormone with an expanded genetic code by Cho, Ho, Daniel, Tom, Buechler, Ying Ji, Litzinger, David C, Maio, Zhenwei, Putnam, Anna-Maria Hays, Kraynov, Vadim S, Sim, Bee-Cheng, Bussell, Stuart, Javahishvili, Tsotne, Kaphle, Sami, Viramontes, Guillermo, Ong, Mike, Chu, Stephanie, GC, Becky, Lieu, Ricky, Knudsen, Nick, Castiglioni, Paola, Norman, Thea C, Axelrod, Douglas W, Hoffman, Andrew R, Schultz, Peter G, DiMarchi, Richard D, Kimmel, Bruce E

“…The ribosomal incorporation of nonnative amino acids into polypeptides in living cells provides the opportunity to endow therapeutic proteins with unique…”
Get full text

FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents by MU, James, PINKSTAFF, Jason, WU, Margaret, NORMAN, Thea C, RODRIGUEZ, Carlos G, KIMMEL, Bruce, METZGER, Joseph M, MANIBUSAN, Anthony, LEE, Darin, ZALLER, Dennis M, ZHANG, Bei B, DIMARCHI, Richard D, ZHIHUA LI, BERGER, Joel P, AXELROD, Douglas W, SKIDMORE, Lillian, NINA LI, MYLER, Heather, DALLAS-YANG, Qing, PUTNAM, Anna-Maria, JUN YAO, BUSSELL, Stuart

“…Fibroblast growth factor 21 (FGF21) mitigates many of the pathogenic features of type 2 diabetes, despite a short circulating half-life. PEGylation is a proven…”
Get full text

Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21 by Müller, Timo D., Sullivan, Lorraine M., Habegger, Kirk, Yi, Chun-Xia, Kabra, Dhiraj, Grant, Erin, Ottaway, Nickki, Krishna, Radha, Holland, Jenna, Hembree, Jazzminn, Perez-Tilve, Diego, Pfluger, Paul T., DeGuzman, Michael J., Siladi, Marc E., Kraynov, Vadim S., Axelrod, Douglas W., DiMarchi, Richard, Pinkstaff, Jason K., Tschöp, Matthias H.

“…The identification of leptin as a mediator of body weight regulation provided much initial excitement for the treatment of obesity. Unfortunately, leptin…”
Get full text

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial by Harris, Steven T, Watts, Nelson B, Genant, Harry K, McKeever, Clark D, Hangartner, Thomas, Keller, Michael, Chesnut III, Charles H, Brown, Jacques, Eriksen, Erik F, Hoseyni, Mohammad S, Axelrod, Douglas W, Miller, Paul D, for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

“…CONTEXT Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other metabolic bone diseases but,…”
Get full text

Risedronate therapy prevents corticosteroid‐induced bone loss : A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study by Cohen, Stanley, Levy, Robert M., Keller, Michael, Boling, Eugene, Emkey, Ronald D., Greenwald, Maria, Zizic, Thomas M., Wallach, Stanley, Sewell, Kathryn L., Lukert, Barbara P., Axelrod, Douglas W., Chines, Arkadi A.

“…Objective Risedronate, a new pyridinyl bisphosphonate, is a potent antiresorptive bone agent. This study examines the safety and efficacy of daily, oral…”
Get full text

Tribute to Harold M. Frost M.D by Turner, Charles, Burr, David, Jee, Webster S S, Smith, Scott, Recker, Robert R, Axelrod, Douglas W, Takahashi, Hideaki E, Villanueva, Antonio R, High, Wanda B, Martin, R Bruce, Parfitt, A Michael

Get full text

Risedronate in Paget's disease: preliminary results of a multicenter study by Brown, J P, Kylstra, J W, Bekker, P J, Axelrod, D W, Siris, E S, Altman, R D, Singer, F R

Get more information